| Name | Title | Contact Details |
|---|
Medicilon Inc. is a prominent Contract Research Organization (CRO) based in Shanghai, China, established in 2004. The company specializes in comprehensive preclinical drug discovery and development services, helping pharmaceutical and biotech clients progress from concept to Investigational New Drug (IND) filing. With over 300,000 square feet of lab space and a team of more than 2,400 scientists, Medicilon is recognized for its expertise and innovation in the field. The company offers a wide range of services, including drug discovery, CMC development, and preclinical research. Their capabilities encompass precision chemical synthesis, GMP-compliant API manufacturing, and extensive pharmacology and toxicology studies. Medicilon adheres to FDA methodologies and international standards, ensuring regulatory compliance throughout the development process. With a focus on client-centric solutions, Medicilon has successfully conducted over 10,000 studies and serves more than 2,000 clients worldwide, emphasizing long-term partnerships and support for drug development programs.
BioStar Consulting, Inc. is a Greenbrier, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cyagen Biosciences is an emerging and innovative biotechnology company that specializes in custom murine model generation, DNA vector construction and viral packaging services. We also offer a comprehensive catalog of stem cell lines, cell culture reagents and growth factors. Our rapidly expanding services portfolio features VectorBuilder – an online DNA vector construction platform designed to make tedious cloning projects obsolete. Let us provide the knowledge and resources to move your project forward, and get you back to discovery!
Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
Seraxis is a privately owned biotechnology company. Our GMP lab is located in Germantown, Maryland, in the heart of the vibrant BioHealth Capital Region. Launched in early 2013, Seraxis used proprietary technologies to develop a cell replacement therapy, SR-01, that is more effective and safer than embryonic stem cell-derived therapies.